Literature DB >> 22827579

The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.

Iain J Nixon1, Monica M Whitcher, Frank L Palmer, R Michael Tuttle, Ashok R Shaha, Jatin P Shah, Snehal G Patel, Ian Ganly.   

Abstract

BACKGROUND: Distant metastases at presentation are rare in well-differentiated thyroid cancer (WDTC). The objective of this study was to report outcomes for patients presenting with distant metastases managed by thyroidectomy and radioactive iodine (RAI) therapy.
METHODS: Fifty-two patients with distant metastases from thyroid cancer diagnosed before thyroid surgery (n=32) or on a postoperative RAI scan after thyroid surgery (n=20) were identified from a database of patients with WDTC treated between 1985 and 2005. The median age was 58 years (range 12-83 years), with a male-to-female ratio of 3:2. Forty-seven patients (90%) had total thyroidectomy and two (4%) had thyroid lobectomy, and three patients (6%) were found to be unresectable. Distant metastases were classified into pulmonary and extrapulmonary. Overall survival (OS), disease-specific survival (DSS), and locoregional recurrence-free survival were calculated by the Kaplan-Meier method. Factors predictive of the outcome were determined by univariate and multivariate analyses.
RESULTS: Thirty-nine patients (75%) were diagnosed with pulmonary metastases alone and 13 (25%) with extrapulmonary metastases. The sites of extrapulmonary metastases were bone in nine, mediastinum in one, pyriform sinus in one and skin in one, and one patient had synchronous lung, bone, and intracerebral metastases. After thyroid surgery, 47 patients (90%) were treated with RAI alone, and 2 patients had external beam radiation in addition to RAI. With a median follow-up after surgery of 78.5 months, the 5-year OS and DSS were 65% and 68%, respectively. Twenty-nine patients (56%) died during follow-up, of whom 24 (46%) died of thyroid cancer. Six patients (12%) developed recurrent disease in the lateral neck, and three patients (6%) developed recurrence in the thyroid bed. Over 45 years, follicular pathology and extrapulmonary metastases were predictive of lower 5-year DSS (56% vs. 100%, p<0.001; 50% vs. 70%, p=0.004; and 46% vs. 75%, p=0.013, respectively).
CONCLUSION: Approximately half of patients with WDTC presenting with distant metastases die of disease within 5 years of initial diagnosis despite thyroid surgery and RAI. Age over 45 years, extrapulmonary metastases, and follicular pathology were significant predictors of the poor outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827579      PMCID: PMC3714454          DOI: 10.1089/thy.2011.0535

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  23 in total

1.  The British Thyroid Association guidelines for the management of thyroid cancer in adults.

Authors:  John C Watkinson
Journal:  Nucl Med Commun       Date:  2004-09       Impact factor: 1.690

2.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.

Authors:  M Schlumberger; C Challeton; F De Vathaire; J P Travagli; P Gardet; J D Lumbroso; C Francese; F Fontaine; M Ricard; C Parmentier
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

3.  Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.

Authors:  J D Lin; M J Huang; J H Juang; T C Chao; B Y Huang; K W Chen; J Y Chen; K L Li; J F Chen; Y S Ho
Journal:  Thyroid       Date:  1999-12       Impact factor: 6.568

4.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

5.  Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades.

Authors:  S F Dinneen; M J Valimaki; E J Bergstralh; J R Goellner; C A Gorman; I D Hay
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

6.  Risk group stratification and prognostic factors in papillary carcinoma of thyroid.

Authors:  A R Shaha; J P Shah; T R Loree
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

7.  Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors.

Authors:  Jandee Lee; Euy-Young Soh
Journal:  Ann Surg       Date:  2010-01       Impact factor: 12.969

8.  Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment.

Authors:  J P Massin; J C Savoie; H Garnier; G Guiraudon; F A Leger; F Bacourt
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

9.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Authors:  I D Hay; E J Bergstralh; J R Goellner; J R Ebersold; C S Grant
Journal:  Surgery       Date:  1993-12       Impact factor: 3.982

10.  Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.

Authors:  D Casara; D Rubello; G Saladini; G Masarotto; A Favero; M E Girelli; B Busnardo
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

View more
  73 in total

Review 1.  Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Francis Worden
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

3.  Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report.

Authors:  Kirsten E Stewart; Mark W J Strachan; Devraj Srinivasan; Morna MacNeill; Lucy Wall; Iain J Nixon
Journal:  Eur Thyroid J       Date:  2019-01-17

4.  Clinical and prognostic role of detection timing of distant metastases in patients with differentiated thyroid cancer.

Authors:  Domenico Albano; Maria Beatrice Panarotto; Rexhep Durmo; Carlo Rodella; Francesco Bertagna; Raffaele Giubbini
Journal:  Endocrine       Date:  2018-08-15       Impact factor: 3.633

5.  Long-Term Outcome of Follicular Thyroid Carcinoma in Patients Undergoing Surgical Intervention for Skeletal Metastases.

Authors:  Anjali Mishra; Chitresh Kumar; Gyan Chand; Gaurav Agarwal; Amit Agarwal; Ashok Kumar Verma; Saroj Kanta Mishra
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

6.  Patterns of metastasis in follicular thyroid carcinoma and the difference between early and delayed presentation.

Authors:  R Parameswaran; J Shulin Hu; N Min En; W B Tan; N K Yuan
Journal:  Ann R Coll Surg Engl       Date:  2016-09-23       Impact factor: 1.891

7.  Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy.

Authors:  Teng Zhao; Jun Liang; Tianjun Li; Wen Gao; Yansong Lin
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

8.  Differentiated thyroid cancer presenting with distant metastases: a population analysis over two decades.

Authors:  Paolo Goffredo; Julie A Sosa; Sanziana A Roman
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

Review 9.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

10.  Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies.

Authors:  Eyal Robenshtok; Azeez Farooki; Ravinder K Grewal; R Michael Tuttle
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.